Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa crossover trial of MK-3577 in type 2 diabetes mellitus with insufficient glycemic control
2009-009517-18Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-3577 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoint: 24-hour Weighted Mean Glucose (WMG). Started Feb 2009; status: terminated.
02
Drugs
MK-3577
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-009517-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009517-18.